Interactions between antiretrovirals and antineoplastic drug therapy

Clinical Pharmacokinetics

Volumn 44, Issue 2, 2005, Pages 111-145

  Antoniou, Tony ^a   Tseng, Alice L ^b,c  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; AMPRENAVIR; ANASTROZOLE; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOCHROME P450; CYTOCHROME P450 2B6; CYTOCHROME P450 3A4; DAUNORUBICIN; DELAVIRDINE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; DRUG METABOLITE; EFAVIRENZ; GLYCOPROTEIN P; IFOSFAMIDE; ISOENZYME; LETROZOLE; PACLITAXEL; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TAMOXIFEN; TAXANE DERIVATIVE; UNINDEXED DRUG; VINCA ALKALOID;

ADRENAL SUPPRESSION; ALOPECIA; ANEMIA; AUTONOMIC NEUROPATHY; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CARDIOTOXICITY; CAUSE OF DEATH; CHEMOTHERAPY INDUCED EMESIS; CHRONIC DRUG ADMINISTRATION; CLINICAL TRIAL; CONCENTRATION RESPONSE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; ENZYME SUBSTRATE; FEBRILE NEUTROPENIA; FEMALE; GRANULOCYTOPENIA; HEART ARRHYTHMIA; HEMORRHAGIC CYSTITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOT FLUSH; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOPENIA; LIVER DYSFUNCTION; METABOLIC ACTIVATION; MORBIDITY; MORTALITY; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVIEW; SIDE EFFECT; SURVIVAL; THROMBOCYTOPENIA;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG INTERACTIONS; HIV INFECTIONS; HUMANS;

EID: 13244290307     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200544020-00001     Document Type: Review

References (261)

1. Palella FJJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853-60
2. Cameron DW, Heath-Chiozzi M, Danner S, et al. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group. Lancet 1998; 351: 543-9
3. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997; 337: 725-33
4. Van Cleef G, Fisher EJ, Polk RE. Drug interaction potential with inhibitors of HIV protease. Pharmacotherapy 1997; 17: 774-8
5. Preston SL, Postelnick M, Purdy BD, et al. Drug interactions in HIV-positive patients initiated on protease inhibitor therapy [letter]. AIDS 1998; 12: 228-30
6. von Moltke LL, Greenblatt DY, Grassi JM, et al. Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir. J Clin Pharmacol 1998; 38: 106-11
7. von Moltke LL, Greenblatt DJ, Granda BW, et al. Inhibition of cytochrome P450 isoforms by non-nucleoside reverse transcriptase inhibitors. J Clin Pharmacol 2001; 41: 85-91
8. Deeks SG, Smith M, Holodniy M, et al. HIV-1 protease inhibitors: a review for clinicians. JAMA 1997; 277: 145-53
9. Barry M, Gibbons S, Back D, et al. Protease inhibitors in patients with HIV disease: clinically important pharmacokinetic considerations. Clin Pharmacokinet 1997; 32: 194-209
10. Piscitelli SC, Flexner C, Minor JR, et al. Drug interactions in patients infected with HIV. Clin Infect Dis 1996; 23: 685-93
11. Barry M, Mulcahy F, Merry C, et al. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. Clin Pharmacokinet 1999; 36: 289-304
12. Tseng AL, Foisy MM. Management of drug interactions in patients with HIV. Ann Pharmacother 1997; 31: 1040-58
13. Efavirenz (Sustiva®) product monograph. Princeton (NJ): Bristol Myers Squibb Pharma, 2002 Feb
14. Orrick JJ, Steinhart CR. Atazanavir. Ann Pharmacother 2004; 38: 1664-74
15. Walmsley S, Leith J, Katlama C, et al. Pharmacokinetics and safety of tipranavir/ritonavir (TPV/r) alone or in combination with saquinavir (SQV), amprenavir (APV), or lopinavir (LPV): interim analysis of BI1182.51 [abstract no. We-OrB1236]. XV International AIDS Conference; 2004 Jul 11-16; Bangkok
16. van Heeswijk R, Sabo JP, Cooper C, et al. The pharmacokinetic interactions between tipranavir/ritonavir 500/200mg bid (TPV/r) and atorvastatin, antacid and CYP3A4 in healthy adult volunteers [abstract no. 5.2]. 5th International Workshop on Clinical Pharmacology of HIV Therapy; 2004 Apr 1-3; Rome
17. Bonnet F, Mortal P, Chene G, et al. Causes of death among HIV-infected patients in the era of highly active antiretroviral therapy, Bordeaux, France, 1998-1999. HIV Med 2002; 3: 195-9
18. Cohen MH, French AL, Benning L, et al. Causes of death among women with human immunodeficiency virus infection in the era of combination antiretroviral therapy. Am J Med 2002; 113: 91-8
19. Louie JK, Hsu LC, Osmond DH, et al. Trends in causes of death among persons with acquired immunodeficiency syndrome in the era of highly active antiretroviral therapy, San Francisco, 1994-1998. J Infect Dis 2002; 186: 1023-7
20. Jones JL, Hanson DL, Sworkin MS, et al. Incidence and trends in Kaposi's sarcoma in the era of effective antiretroviral therapy. J Acquir Immune Defic Syndr 2000; 24: 270-4
21. Ledergerber B, Egger M, Erard V, et al. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA 1999; 282: 2220-6
22. Carrieri MP, Pradier C, Piselli P, et al. Reduced incidence of Kaposi's sarcoma and of systemic non-Hodgkin's lymphoma in HIV-infected individuals treated with highly active antiretroviral therapy. Int J Cancer 2003; 103: 142-4
23. Kirk O, Pederson C, Cozzi-Lepri A, et al. Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. Blood 2001; 98: 3406-12
24. Dal Maso L, Franceschi S. Epidemiology of non-Hodgkin lymphomas and other haemolymphopoietic neoplasms in people with AIDS. Lancet Oncol 2003; 4: 110-9
25. Dal Maso L, Serraino D, Franceschi S. Epidemiology of AIDS-related tumours in developed and developing countries. Eur J Cancer 2001; 37: 1188-201
26. Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 1997; 32: 210-58
27. Gerard L, Galicier L, Boulanger E, et al. Improved survival in HIV-related Hodgkin's lymphoma since the introduction of highly active antiretroviral therapy. AIDS 2003; 17: 81-7
28. Tulpule A, Groopman J, Saville MW, et al. Multicenter trial of low-dose paclitaxel in patients with AIDS-related Kaposi sarcoma. Cancer 2002; 95: 147-54
29. Gill PS, Tulpule A, Espina BM, et al. Paclitaxel is safe and effective in the treatment of advanced AIDS-related Kaposi's sarcoma. J Clin Oncol 1999; 17: 1876-83
30. Welles L, Saville MW, Lietzau J, et al. Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma. J Clin Oncol 1998; 16: 1112-21
31. Cresteil T, Monsarrat B, Dubois J, et al. Regioselective metabolism of taxoids by human CYP3A4 and 2C8: structure-activity relationship. Drug Metab Dispos 2002; 30: 438-45
32. Rahman A, Korzekwa KR, Grogan J, et al. Selective biotransformation of taxol to 6 α-hydroxytaxol by human cytochrome P450 2C8. Cancer Res 1994; 54: 5543-6
33. Cresteil T, Monsarrat B, Alvinerie P, et al. Taxol metabolism by human liver microsomes: identification of cytochrome P450 involved in its biotransformation. Cancer Res 1994; 54: 386-92
34. Monsarrat B, Royer I, Wright M, et al. Biotransformation of taxoids by human cytochromes P450: structure-activity relationship. Bull Cancer 1997; 84: 125-33
35. Kumar G, Ray S, Walle T, et al. Comparative in vitro cytotoxic effects of taxol and its major human metabolite 6 α-hydroxytaxol. Cancer Chemother Pharmacol 1995; 36: 129-35
36. Monsarrat B, Mariel E, Gros S, et al. Taxol metabolism: isolation and identification of three major metabolites of taxol in rat bile. Drug Metab Dispos 1990; 18: 895-901
37. Harris JW, Katki A, Anderson LW, et al. Isolation, structural determination, and biological activity of 6 α-hydroxytaxol, the principal human metabolite of taxol. J Med Chem 1994; 37: 706-9
38. Panday VRN, Hoetelmans RMW, van Heeswijk RPG, et al. Paclitaxel in the treatment of human immunodeficiency virus 1-associated Kaposi's sarcoma: drug-drug interactions with protease inhibitors and a nonnucleoside reverse transcriptase inhibitor: a case report study. Cancer Chemother Pharmacol 1999; 43: 516-9
39. Duchin K, Sun J, Tan M, et al. Pharmacokinetics of low-dose Paxene™ (paclitaxel) in patients with refractory or relapsed AIDS-related Kaposi's sarcoma [abstract no. 829]. 33rd Annual Meeting of the American Society of Clinical Oncology; 1997 May 17-20; Denver
40. Schwartz JD, Howard M, Scadden DT. Potential interaction of antiretroviral therapy with paclitaxel in patients with AIDS-related Kaposi's sarcoma. AIDS 1999; 13: 283-4
41. Parameswaran R, Svreeney C, Einhorn LH. Interaction between highly active antiretroviral therapy (HAART) and taxines: a report of two cases [abstract no. 2194]. 38th Annual Meeting of the American Society of Clinical Oncology; 2002 May 18-21; Orlando
42. Marre F, Sanderink GJ, de Sousa G, et al. Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans. Cancer Res 1996; 56: 1296-302
43. Hirth J, Watkins PB, Strawderman M, et al. The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance. Clin Cancer Res 2000; 6: 1255-8
44. Royer I, Monsarrat B, Sonnier M, et al. Metabolism of docetaxel by human cytochromes P450: interactions with paclitaxel and other antineoplastic drugs. Cancer Res 1996; 56: 56-65
45. Bardelmeijer HA, Ouwehand M, Buckle T, et al. Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir. Cancer Res 2002; 62: 6158-84
46. Villikka K, Kivisto KT, Maenpaa H, et al. Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors. Clin Pharmacol Ther 1999; 66: 589-93
47. Bohme A, Ganser A, Hoelzer D. Aggravation of vincristine-induced neurotoxicity by itraconazole in the treatment of adult ALL. Ann Hematol 1995; 71: 311-2
48. Kamaluddin M, McNally P, Breatnach F, et al. Potentiation of vincristine toxicity by itraconazole in children with lymphoid malignancies. Acta Paediatr 2001; 90: 1204-7
49. Zhou-Pan XR, Seree E, Zhou XJ, et al. Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions. Cancer Res 1993; 53: 5121-6
50. Kajita J, Kuwabara T, Kobayashi H, et al. CYP3A4 is mainly responsible for the metabolism of a new vinca alkaloid, vinorelbine, in human liver microsomes. Drug Metab Dispos 2000; 28: 1121-7
51. Yao D, Ding S, Burchell B, et al. Detoxification of vinca alkaloids by human P450 CYP3A4-mediated metabolism: implications for the development of drug resistance. J Pharmacol Exp Ther 2000; 294: 387-95
52. Relling MV, Evans R, Dass C, et al. Human cytochrome P450 metabolism of teniposide and etoposide. J Pharmacol Exp Ther 1992; 261: 491-6
53. Relling MV, Nemec J, Schuetz EG, et al. O-demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4. Mol Pharmacol 1994; 45: 352-8
54. Kawashiro T, Yamashita K, Zhao XJ, et al. A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes. J Pharmacol Exp Ther 1998; 286: 1294-300
55. Zhao XJ, Kawashiro T, Ishizaki T. Mutual inhibition between quinine and etoposide by human liver microsomes: evidence for cytochrome P450 3A4 involvement in their major metabolic pathways. Drug Metab Dispos 1997; 26: 188-91
56. Mathijssen RHJ, van Alpen RJ, Verweij J, et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 2001; 7: 2182-94
57. Cersosimo RJ. Topotecan: a new topoisomerase I inhibiting antineoplastic agent. Ann Pharmacother 1998; 32: 1334-43
58. Garcia-Carbonero R, Supko JG. Current perspectives on the clinical experience, pharmacology and continued development of the camptothecins. Clin Cancer Res 2002; 8: 641-61
59. Herben VMM, Schoemaker NE, Rosing H, et al. Urinary and fecal excretion of topotecan in patients with malignant solid tumours. Cancer Chemother Pharmacol 2002; 50: 59-64
60. Chang TK, Weber GF, Crespi CL, et al. Differential activation of cyclophosphamide and ifosphamide by cytochromes P450 2B and 3A in human liver microsomes. Cancer Res 1993; 53: 5629-37
61. Roy P, Yu LJ, Crespi CL, et al. Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos 1999; 27: 655-66
62. Huang Z, Roy P, Waxman DJ. Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide. Biochem Pharmacol 2000; 59: 961-72
63. Yu L, Waxman DJ. Role of cytochrome P450 in oxazaphosphorine metabolism: deactivation via N-dechloroethylation and activation via 4-hydroxylation catalyzed by distinct subsets of rat liver cytochromes P450. Drug Metab Dispos 1996; 24: 1254-62
64. Granvil CP, Madan A, Sharkawi M, et al. Role of CYP2B6 and CYP3A4 in the in vitro N-dechloroethylation of (R)- and (S)-ifosfamide in human liver microsomes. Drug Metab Dispos 1999; 27: 533-41
65. Roy P, Tretyakov O, Wright J, et al. Stereoselective metabolism of ifosfamide by human P-450s 3A4 and 2B6: favourable metabolic properties of (R)-enantiomer. Drug Metab Dispos 1999; 27: 1309-18
66. Lee FY, Workman P, Roberts JT, et al. Clinical pharmacokinetics of oral CCNU (lomustine). Cancer Chemother Pharmacol 1985; 14: 125-31
67. Wheeler GP, Johnston TP, Bowdon BJ, et al. Comparison of the properties of metabolites of CCNU. Biochem Pharmacol 1977; 26: 2331-6
68. Chang TK, Chen G, Waxman DJ. Modulation of thiotepa antitumor activity in vivo by alteration of liver cytochrome P450-catalyzed drug metabolism. J Pharmacol Exp Ther 1995; 274: 270-5
69. van Maanen MJ, Huitema AD, Beijen JH. Influence of co-medicated drugs on the biotransformation of thioTEPA to TEPA and thioTEPA-mercapturate. Anticancer Res 2000; 20 (3A): 1711-6
70. Jacobson PA, Green K, Birnbaum A, et al. Cytochrome P450 isozymes 3A4 and 2B6 are involved in the in vitro human metabolism of thiotepa to TEPA. Cancer Chemother Pharmacol 2002; 49: 461-7
71. Rae JM, Soukhova NV, Flockhart DA, et al. Triethylenethio-phosphoramide is a specific inhibitor of cytochrome P450 2B6: implications for cyclophosphamide metabolism. Drug Metab Dispos 2002; 30: 525-30
72. Reid JM, Kuffel MJ, Miller JK, et al. Metabolic activation of dacarbazine by human cytochromes P450: the role of CYP1A1, CYP1A2, and CYP2E1. din Cancer Res 1999; 5: 2192-7
73. Damia G, D'Incalci M. Clinical pharmacokinetics of altretamine. Clin Pharmacokinet 1995; 28: 439-48
74. Karunanayake EH, Hearse DJ, Mellows G. The metabolic fate and elimination of streptozocin. Biochem Soc Trans 1975; 3: 410-4
75. Weiss RB. Streptozocin: a review of its pharmacology, efficacy, and toxicity. Cancer Treat Rep 1982; 66: 427-38
76. Goria-Gatti L, Iannone A, Tomasi A, et al. In vitro and in vivo evidence for the formation of methyl radical from procarbazine: a spin trapping study. Carcinogenesis 1992; 13: 799-805
77. Kasel D, Baumhakel M, Fuhr U. Biodegradation of procarbazine by human liver microsomes. Int J Clin Pharmacol Ther 2000; 38: 153-5
78. Czerwinski M, Gibbs JP, Slattery JT. Busulfan conjugation by glutathione S-transferases α, μ, and pi. Drug Metab Dispos 1996; 24: 1015-9
79. Gibbs JP, Czerwinski M, Slattery JT. Busulfan-glutathione conjugation catalyzed by human liver cytosolic glutathione S-transferases. Cancer Res 1996; 56: 3678-81
80. Poonkuzhali B, Chandy M, Srivastava A, et al. Glutathione S-transferase activity influences busulfan pharmacokinetics in patients with beta thalassemia major undergoing bone marrow transplantation. Drug Metab Dispos 2001; 29: 264-7
81. Marchand DH, Remmel RP, Abdel-Monem MM. Biliary excretion of a glutathione conjugate of busulfan and 1,4-diiodobutane in the rat. Drug Metab Dispos 1993; 16: 85-92
82. Buggia I, Zecca M, Alessandrino EP, et al. Itraconazole can increase systemic exposure to busulfan in patients given bone marrow transplantation. GITMO (Gruppo Italiano Trapianto di Midollo Osseo). Anticancer Res 1996; 16: 2083-8
83. McLean A, Newell D, Baker G, et al. The metabolism of chlorambucil. Biochem Pharmacol 1980; 29: 2039-47
84. Alberts DS, Chang SY, Chen HS, et al. Comparative pharmacokinetics of chlorambucil and melphalan in man. Recent Results Cancer Res 1980; 74: 124-31
85. Alberts DS, Chang SY, Chen HS, et al. Kinetics of intravenous melphalan. Clin Pharmacol Ther 1979; 26: 73-80
86. Gormley PE, Bull JM, LeRoy AF, et al. Kinetics of cis- dichlorodiammineplatinum. Clin Pharmacol Ther 1979; 25: 351-7
87. Jacobs C, Kaiman SM, Tretton M, et al. Renal handling of cis-diamminedichloroplatinum(II). Cancer Treat Rep 1980; 64: 1223-6
88. LeRoy AF, Lutz RJ, Dedrick RL, et al. Pharmacokinetic study of cis-diamminedichloroplatinum(II) (DDP) in the beagle dog: thermodynamic and kinetic behaviour of DDP in a biologic milieu. Cancer Treat Rep 1979; 63: 59-71
89. Go RS, Adjei AA. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 1999; 17: 409-22
90. Product monograph. Mustargen (mechlorethamine). West Point (PA): Merck & Co Inc., 1999 Mar
91. Bachur NR. Adriamycin (NSC-123127) pharmacology. Cancer Chemother Rep 1975; 6: 153-8
92. Takanashi S, Bachur NR. Adriamycin metabolism in man. Drug Metab Dispos 1967; 4: 79-87
93. Benjamin RS, Riggs CE, Bachur NR. Plasma pharmacokinetics of adriamycin and its metabolites in humans with normal renal and hepatic function. Cancer Res 1977; 37: 1416-20
94. Riggs CE, Benjamin RS, Serpick AA, et al. Biliary disposition of adriamycin. Clin Pharmacol Ther 1977; 22: 234-41
95. Goeptar AR, Te Koppele JM, Lamme EK, et al. Cytochrome P450 2B1-mediated one-electron reduction of adriamycin: a study with rat liver microsomes and purified enzymes. Mol Pharmacol 1993; 44: 1267-77
96. Goeptar AR, Groot EF, Scheerens H, et al. Cytotoxicity of mitomycin C and adriamycin in freshly isolated rat hepatocytes: the role of cytochrome P450. Cancer Res 1994; 54: 2411-8
97. Coukell AJ, Spencer CM. Polyethylene glycol-liposomal doxorubicin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi's Sarcoma. Drugs 1997; 53: 520-38
98. Amantea MA, Forrest A, Northfelt DW, et al. Population pharmacokinetics and pharmacodynamics of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi's sarcoma. Clin Pharmacol Ther 1997; 61: 301-11
99. Loveless H, Arena E, Felsted RL, et al. Comparative mammalian metabolism of adriamycin and daunorubicin. Cancer Res 1978; 38: 593-8
100. Takanashi S, Bachur NR. Daunorubicin metabolites in human urine. J Pharmacol Exp Ther 1975; 195: 41-9
101. Lown JW, Chen HH. Electron paramagnetic resonance characterization and conformation of daunorubicin semiquinone intermediate implicated in anthracycline metabolism, cardiotoxicity, and anticancer action. Can J Chem 1981; 59: 3212-7
102. Fumagalli LLF, Zucchetti M, Vigano MG, et al. Treatment of HIV-associated non-Hodgkin's lymphoma with liposomal daunorubicin substituted CHOP and HAART: preliminary clinical results and CSF pharmacokinetic [abstract no. 136]. American Society of Clinical Oncology, 36th Annual Meeting; 2000 May 19-23; New Orleans
103. Girard PM, Bouchaud O, Goetschel A, et al. Phase II study of liposomal encapsulated daunorubicin in the treatment of AIDS-associated mucocutaneous Kaposi's sarcoma. AIDS 1996; 10: 753-7
104. Gill PS, Wernz J, Scadden DT, et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J Clin Oncol 1996; 14: 2353-64
105. Melosky B, Gelmon K. Phase II trial of liposomal daunorubicin with concurrent protease inhibitors in AIDS-related Kaposi's sarcoma [abstract no. 34]. J Acquir Immune Defic Syndr 2000; 23: A23
106. Fumagalli L, Zucchetti M, Parisi I, et al. The pharmacokinetics of liposomal encapsulated daunorubicin are not modified by HAART in patients with HIV-associated Kaposi's sarcoma. Cancer Chemother Pharmacol 2000; 45: 495-501
107. Tattersall MHN, Scdergren JE, Sengupta SK, et al. Pharmacokinetics of actinomycin D in patients with malignant melanoma. Clin Pharmacol Ther 1975; 17: 701-8
108. Mross K, Maessen P, van der Vijgh WJ, et al. Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans. J Clin Oncol 1988; 6: 517-26
109. Weenen H, Lankelma J, Penders PG, et al. Pharmacokinetics of 4-epi-doxorubicin in man. Invest New Drugs 1983; 1: 59-64
110. Tjuljandin SA, Doig RG, Sobol MM, et al. Pharmacokinetics and toxicity of two schedules of high dose epirubicin. Cancer Res 1990; 50: 5095-101
111. Innocenti F, Iyer L, Ramirez J, et al. Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7. Drug Metab Dispos 2001; 29: 686-92
112. Cairo MS, Toy C, Sender L, et al. Effect of idarubicin and epirubicin on in vitro polymorphonuclear function: diminished superoxide radical formation compared to their parent compounds daunorubicin and doxorubicin. J Leukoc Bio 1990; 47: 224-33
113. Gillies HC, Herriot D, Liang R, et al. Pharmacokinetics of idarubicin (4-demethoxydaunorubicin; IMI-30; NSC 256439) following intravenous and oral administration in patients with advanced cancer. Br J Clin Pharmacol 1987; 23: 303-10
114. Camaggi CM, Strocchi E, Carisi P, et al. Idarubicin metabolism and pharmacokinetics after intravenous and oral administration in cancer patients: a crossover study. Cancer Chemother Pharmacol 1992; 30: 307-16
115. Kerpel-Fronius S, Verwey J, Stuurman M, et al. Pharmacokinetics and toxicity of mitomycin C in rodents, given alone, in combination, or after induction of microsomal drug metabolism. Cancer Chemother Pharmacol 1988; 22: 104-8
116. Crooke ST, Henderson M, Samson M, et al. Phase I study of oral mitomycin C. Cancer Treat Rep 1976; 60: 1633-6
117. den Hartigh J, McVie JG, van Oort WJ, et al. Pharmacokinetics of mitomycin C in humans. Cancer Res 1983; 43: 5017-21
118. Cummings J, Spanswick VJ, Tomasz M, et al. Enzymology of mitomycin C metabolic activation in tumour tissue. Biochem Pharmacol 1998; 56: 405-14
119. Chiccarelli FS, Morrison JA, Cosulich DB, et al. Identification of human urinary mitoxantrone metabolites. Cancer Res 1986; 46: 4858-61
120. Ehninger G, Proksch B, Heinzel G, et al. Clinical pharmacology of mitoxantrone. Cancer Treat Rep 1986; 70: 1373-8
121. Blanz J, Mewes K, Ehninger G, et al. Evidence for oxidative activation of mitoxantrone in human, pig, and rat. Drug Metab Dispos 1991; 19: 871-80
122. Mewes K, Blanz J, Ehninger G, et al. Cytochrome P-450-induced cytotoxicity of mitoxantrone by formation of electrophilic intermediates. Cancer Res 1993; 53: 5135-42
123. Duthie SJ, Grant MH. The role of reductive and oxidative metabolism in the toxicity of mitoxantrone, adriamycin and menadione in human liver derived HepG2 hepatoma cells. Br J Cancer 1989; 60: 566-71
124. Balis FM, Holcenberg JS, Bleyer WA. Clinical pharmacokinetics of commonly used anticancer drugs. Clin Pharmacokinet 1983; 8: 202-32
125. Montgomery MR, Furry J, Fernandez S. Bleomycin inhibits hepatic mixed function oxidation. Res Commun Chem Pathol Pharmacol 1981; 34: 287-93
126. Crewe HK, Ellis SW, Lennard MS, et al. Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. Biochem Pharmacol 1997; 53: 171-8
127. Jacolot F, Simon I, Dreano I, et al. Identification of the cytochrome P450 IIIA family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes. Biochem Pharmacol 1991; 41: 1911-9
128. Crewe HK, Notley LM, Wunsch RM, et al. Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4′-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos 2002; 30: 869-74
129. Fabian C, Tilzer L, Sternson L. Comparative binding affinities of tamoxifen, 4-hydroxytamoxifen, and desmethyltamoxifen for estrogen receptors isolated from human breast carcinoma: correlation with blood levels in patients with metastatic breast cancer. Biopharm Drug Dispos 1981; 2: 381-90
130. Coezy E, Borgna JL, Rochefort H. Tamoxifen and metabolites in MCF7 cells: correlation between binding to estrogen receptor and inhibition of cell growth. Cancer Res 1982; 42: 317-23
131. Mandlekar S, Hebbar V, Christov K, et al. Pharmacodynamics of tamoxifen and its 4-hydroxy and N-desmethyl metabolites: activation of caspases and induction of apoptosis in rat mammary tumors and in human breast cancer cell lines. Cancer Res 2000; 60: 6601-6
132. Jordan VC, Collins MM, Rowsby L, et al. A monohydroxylated metabolite of tamoxifen with potent antiestrogenic activity. J Endocrinol 1977; 75: 305-16
133. Boocock DJ, Brown K, Gibbs AH, et al. Identification of human CYP forms involved in the activation of tamoxifen and irreversible binding to DNA. Carcinogenesis 2002; 23: 1897-901
134. Shibutani S, Ravindernath A, Suzuki N, et al. Identification of tamoxifen-DNA adducts in the endometrium of women treated with tamoxifen. Carcinogenesis 2000; 21: 1461-7
135. White IN, De Matteis F, Gibbs AH, et al. Species differences in the covalent binding of [14C]tamoxifen to liver microsomes and the forms of cytochrome P450 involved. Biochem Pharmacol 1995; 49: 1035-42
136. Stiborova M, Borek-Dohalska L, Hodek P, et al. New selective inhibitors of cytochromes P450 2B and their application to antimutagenesis of tamoxifen. Arch Biochem Biophys 2002; 403: 41-9
137. Kivisto KT, Villikka K, Nyman L, et al. Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin. Clin Pharmacol Ther 1998; 64: 648-54
138. Daniel PC, Gaskell J, Bishop H, et al. Determination of tamoxifen and biologically active metabolites in human breast tumour and plasma. Eur J Cancer Clin Oncol 1981; 17: 1183-9
139. Desai PB, Nallani SC, Sane RS, et al. Induction of cytochrome P450 3A4 in primary human hepatocytes and activation of the human pregnane X receptor by tamoxifen and 4-hydroxytamoxifen. Drug Metab Dispos 2002; 30: 608-12
140. Cotreau MM, von Moltke LL, Harmatz JS, et al. Molecular and pharmacokinetic evaluation of rat hepatic and gastrointestinal cytochrome p450 induction by tamoxifen. Pharmacology 2001; 63: 210-9
141. Buzdar AU, Robertson JFR, Eirmann W, et al. An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole and exemestane. Cancer 2002; 95: 2006-16
142. Lamb HM, Adkins JC. Letrozole: a review of its use in postmenopausal women with advanced breast cancer. Drugs 1998; 56: 1125-40
143. ATAC Trialists' Group. Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex™ and tamoxifen alone or in combination' (ATAC) trial. Br J Cancer 2001; 85: 317-24
144. Berthou F, Dreano Y, Belloc C, et al. Involvement of cytochrome P450 3A enzyme family in the major metabolic pathways of toremifene in human liver microsomes. Biochem Pharmacol 1994; 47: 1883-95
145. Grill HJ, Follow K. Pharmacokinetics of droloxifene and its metabolites in breast cancer patients. Am J Clin Oncol 1991; 14 Suppl. 2: S21-9
146. Bruning PF. Droloxifene, a new anti-oestrogen in postmenopausal advanced breast cancer: preliminary results of a double-blind dose-finding phase II trial. Eur J Cancer 1992; 28A: 1404-7
147. John BA, Brodie RR, Baldock GA, et al. Pharmacokinetics and metabolism of the anti-oestrogen droloxifene in female human subjects. Xenobiotica 2002; 32: 699-713
148. Lonning PE, Geisler J, Johannessen DC, et al. Pharmacokinetics and metabolism of formestane in breast cancer patients. J Steroid Biochem Mol Biol 2001; 77: 39-47
149. Gentile DM, Tomlinson ES, Maggs JL, et al. Dexamethasone metabolism by human liver in vitro. Metabolite identification and inhibition of 6-hydroxylation. J Pharmacol Exp Ther 1996; 277: 105-12
150. Tomlinson ES, Lewis DFV, Maggs JL, et al. In vitro metabolism of dexamethasone (DEX) in human liver and kidney: the involvement of CYP3A4 and CYP17 (17,20 LYASE) and molecular modelling studies. Biochem Pharmacol 1997; 54: 605-11
151. Vans T, Kivisto KT, Backman JT, et al. Itraconazole decreases the clearance and enhances the effects of intravenously administered methylprednisolone in healthy volunteers. Pharmacol Toxicol 1999; 85: 29-32
152. Vans T, Kaukonen KM, Kivisto KT, et al. Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole. Clin Pharmacol Ther 1998; 64: 363-8
153. Lebrun-Vignes B, Archer VC, Diquet B, et al. Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects. Br J Clin Pharmacol 2001; 51: 443-50
154. Vans T, Kivisto KT, Neuvonen PJ. Grapefruit juice can increase the plasma concentrations of oral methylprednisolone. Eur J Clin Pharmacol 2000; 56: 489-93
155. Varis T, Kivisto KT, Backman JT, et al. The cytochrome P450 3A4 inhibitor itraconazole markedly increases the plasma concentrations of dexamethasone and enhances its adrenal-suppressant effect. Clin Pharmacol Ther 2000; 68: 487-94
156. Ogg MS, Williams JM, Tarbit M, et al. A receptor gene assay to assess the molecular mechanisms of xenobiotic-dependent induction of the human CYP3A4 gene in vitro. Xenobiotica 1999; 29: 269-79
157. McCune JS, Hawke RL, LeCluyse EL, et al. In vivo and in vitro induction of human cytochrome P450 3A4 by dexamethasone Clin Pharmacol Ther 2000; 68: 356-66
158. Yamashita SK, Ludwig EA, Middleton Jr E, et al. Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone. Clin Pharmacol Ther 1991; 49: 558-70
159. Hollander AA, van Rooij J, Lentjes GW, et al. The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients. Clin Pharmacol Ther 1995; 57: 318-24
160. Varis T, Kivisto KT, Neuvonen PJ. The effect of itraconazole on the pharmacokinetics and pharmacodynamics of oral prednisolone. Eur J Clin Pharmacol 2000; 56: 57-60
161. Harris RZ, Tsunoda SM, Mroczkowski P, et al. The effects of menopause and hormone replacement therapies on prednisolone and erythromycin pharmacokinetics. Clin Pharmacol Ther 1996; 59: 429-35
162. Bundow D, Aboulafia DM. Potential drug interaction with paclitaxel and highly active antiretroviral therapy in two patients with AIDS-associated Kaposi Sarcoma. Am J Clin Oncol 2004; 27: 81-4
163. Wen X, Wang JS, Backman JT, et al. Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively. Drug Metab Dispos 2002; 30: 631-5
164. Klecker RW, Jamis-Dow CA, Egorin MJ, et al. Effect of cimetidine, probenecid, and ketoconazole on the distribution, biliary secretion, and metabolism of [3H]taxol in the Sprague-Dawley rat. Drug Metab Dispos 1994; 22: 254-8
165. Jamis-Dow CA, Klecker RW, Katki AG, et al. Metabolism of taxol by human and rat liver in vitro: a screen for drug interactions and interspecies differences. Cancer Chemother Pharmacol 1995; 36: 107-14
166. Slichenmeyer WJ, Donehower RC, Chen TL, et al. Pretreatment H2 receptor antagonists that differ in P450 modulation activity: comparative effects on paclitaxel clearance rates and neutropenia. Cancer Chemother Pharmacol 1995; 36: 227-32
167. Jamis-Dow CA, Pearl ML, Watkins PB, et al. Predicting drug interactions in vivo from experiments in vitro: human studies with paclitaxel and ketoconazole. Am J Clin Oncol 1997; 20: 592-9
168. Sonnichsen DS, Liu Q, Schuetz EG, et al. Variability in human cytochrome P450 paclitaxel metabolism. J Pharmacol Exp Ther 1995; 275: 566-75
169. Dai D, Zeldin DC, Blaisdell JA, et al. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 2001; 11: 597-607
170. Bahadur N, Leathart JBS, Mutch E, et al. CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6α-hydroxylase activity in human liver microsomes. Biochem Pharmacol 2002; 64: 1579-89
171. Kearns CM, Gianni L, Egorin MJ. Paclitaxel pharmacokinetics and pharmacodynamics. Semin Oncol 1995; 22 Suppl. 6: 16-23
172. Engels FK, Ten Tije AJ, Baker SD, et al. Effect of cytochrome P450 3A4 inhibition on the pharamcokinetics of docetaxel. Clin Pharmacol Ther 2004; 75: 448-54
173. Bruno R, Hille D, Riva A, et al. Population pharmacokinetics/
174. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents [online]. Available from URL: http://aidsinfo.nih.gov/guidelines/adult/AA_102904.pdf [Accessed 2004 Nov 10]
175. Chang SM, Kuhn JG, Rizzo J, et al. Phase I study of puclitaxel in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report. J Clin Oncol 1998; 16: 2188-94
176. Kostrubsky VE, Lewis LD, Wood SG, et al. Effect of taxol on cytochrome P450 3A and acetaminophen toxicity in cultured rat hepatocytes: comparison to dexamethasone. Toxicol Appl Pharmacol 1997; 142: 79-86
177. Kostrubsky VE, Lewis LD, Strom SC, et al. Induction of cytochrome P450 3A by Taxol in primary cultures of human hepatocytes. Arch Biochem Biophys 1998; 355: 131-6.
178. Nallani SC, Genter MB, Desai PB. Increased activity of CYP3A enzyme in primary cultures of rat hepatocytes treated with docetaxel: comparative evaluation with paclitaxel. Cancer Chemother Pharmacol 2001; 48: 115-22
179. Nallani SC, Goodwin B, Buckley AR, et al. Differences in the induction of cytochrome P450 3A4 by taxane anticancer drugs, docetaxel and paclitaxel, assessed employing primary human hepatocytes. Cancer Chemother Pharmacol 2004; 54: 219-29
180. Baumhakel M, Kasel D, Rao-Schymanski RA, et al. Screening for inhibitory effects of antineoplastic agents on CYP3A4 in human liver microsomes. Int J Clin Pharmacol Ther 2001; 39: 517-28
181. Nasti G, Errante D, Talamini R, et al. Vinorelbine is an effective and safe drug for AIDS-related Kaposi's sarcoma: results of a phase II study. J Clin Oncol 2000; 18: 1550-7
182. Spina M, Gabarre J, Rossi G, et al. Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection. Blood 2002; 100: 1984-8
183. Errante D, Tirelli U, Gastaldi R, et al. Combined antineoplastic and antiretroviral therapy for patients with Hodgkin's disease and human immunodeficiency virus infection: a prospective study of 17 patients. Cancer 1994; 73: 437-44
184. Kaplan LD, Straus DJ, Testa MA, et al. Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. N Engl J Med 1997; 336: 1641-8
185. Vaccher E, Spina M, di Gennaro G, et al. Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma. Cancer 2001; 91: 155-63
186. Baiocchi OCG, Colleoni GWB, Navajas EV, et al. Impact of highly active antiretroviral therapy in the treatment of HIV-infected patients with systemic non-Hodgkin's lymphoma. Acta Oncol 2002; 41: 192-6
187. Navarro JT, Ribera JM, Oriol A, et al. Influence of highly active anti-retroviral therapy on response to treatment and survival in patients with acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma treated with cyclophosphamide, hydroxydoxorubicin, vincristine and prednisone. Br J Haematol 2001; 112: 909-15
188. Owellen RJ, Hartke CA, Hains FO. Pharmacokinetics and metabolism of vinblastine in humans. Cancer Res 1977; 37: 2597-602
189. Toffoli G, Tolusso B, Vaccher E, et al. Saquinavir and antineoplastic chemotherapy interactions in in vitro human cancer cell lines and in HIV-associated non-Hodgkin's lymphoma (HIV-NHL) patients [abstract no. 2153]. 37th Annual Meeting of the American Society of Clinical Oncology; 2001 May 12-15; San Francisco
190. Cortes J, Thomas D, Rios A, et al. Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia. Cancer 2002; 94: 1492-9
191. Horning SJ, Hoppe RT, Breslin S, et al. Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. J Clin Oncol 2002; 20: 630-7
192. Sparano JA, Wiernik PH, Strack M, et al. Infusional cyclophosphamide, doxorubicin, and etoposide in HIV-related non-Hodgkin's lymphoma: a follow-up report to a highly active regimen. Leuk Lymphoma 1994; 14: 263-71
193. Sparano JA, Wienik PH, Hu X, et al. Pilot trial of infusional cyclophosphamide, doxorubicin, and etoposide plus didanosine and filgrastim in patients with human immunodeficiency virus-associated non-Hodgkin's lymphoma. J Clin Oncol 1996; 14: 3026-35
194. Spina M, Vaccher E, Juzbasic S, et al. Human immunodeficiency virus-related non-Hodgkin lymphoma: activity of infusional cyclophosphamide, doxorubicin, and etoposide as second-line chemotherapy in 40 patients. Cancer 2001; 92: 200-6
195. van Maanen JMS, de Vries J, Pappie D, et al. Cytochrome P-450-mediated O-demethylation: a route in the metabolic activation of etoposide. Cancer Res 1987; 47: 4658-62
196. Mans DR, Retel J, van Maanen JM, et al. Role of the semiquinone free radical of the anti-tumour agent etoposide (VP-16-213) in the inactivation of single- and double-stranded phi X174 DNA. Br J Cancer 1990; 62: 54-60
197. Haim N, Nemec J, Roman J, et al. Peroxidase-catalyzed metabolism of etoposide (VP-16-213) and covalent binding of reactive intermediates to cellular macromolecules. Cancer Res 1987; 47: 5835-40
198. Usui N, Sinha BK. Tyrosinase-induced free radical formation from VP-16,213: relationship to cytotoxicity. Free Radic Res Commun 1990; 10: 287-93
199. Felix CA, Walker AH, Lange BJ, et al. Association of CYP3A4 genotype with treatment-related leukemia. Proc Natl Acad Sci U S A 1998; 95: 13176-81
200. Relling MV, Yanishevski Y, Nemec J, et al. Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia. Leukemia 1998; 12: 346-52
201. Sparano JA, Wiernik PH, Hu X, et al. Saquinavir enhances the mucosal toxicity of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma. Med Oncol 1998; 15: 50-7
202. Sparano JA, Lee S, Chen MG, et al. Phase II trial of infusional cyclophosphamide, doxorubicin and etoposide in patients with HIV-associated non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group trial (E1494). J Clin Oncol 2004; 22: 1491-500
203. Bower M, McCall-Peat N, Ryan N, et al. Protease inhibitors potentiate chemotherapy-induced neutropenia. Blood 2004; 104: 2943-6
204. Baker DK, Relling MV, Pui CH, et al. Increased teniposide clearance with concomitant anticonvulsant therapy. J Clin Oncol 1992; 10: 311-5
205. Kehrer DFS, Mathijssen RHJ, Verweij J, et al. Modulation of irinotecan metabolism by ketoconazole. J Clin Oncol 2002; 20: 3122-9
206. Mathijssen RHJ, Verweij J, de Bruijn P, et al. Effects of St John's wort on irinotecan metabolism. J Natl Cancer Inst 2002; 94: 1247-9
207. Murry DJ, Cherrick I, Salama V, et al. Influence of phenytoin on the disposition of irinotecan: a case report. J Pediatr Hematol Oncol 2002; 24: 130-3
208. Gajjar A, Radomski K, Bowers D, et al. Pharmacokinetics of irinotecan (IRN) and metabolites in pediatric high-grade glioma patients with and without co-administration of enzyme-inducing anticonvulsants [abstract no. 626]. 36th Annual Meeting of the American Society of Clinical Oncology; 2000 May 19-23; New Orleans
209. Gupta E, Wang X, Ramirez J, et al. Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital. Cancer Chemother Pharmacol 1997; 40: 440-4
210. Rosing H, Herben VMM, van Gortel-van Zomeren EH, et al. Isolation and structural confirmation of N-desmethyl topotecan, a metabolite of topotecan. Cancer Chemother Pharmacol 1997; 39: 498-504
211. Rosing H, van Zomeren DM, Doyle E, et al. O-glucuronidation, a newly identified metabolic pathway for topotecan and N-desmethyl topotecan. Anticancer Drugs 1998; 9: 587-92
212. Zamboni WC, Gajjar AJ, Heideman RL, et al. Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastorna. Clin Cancer Res 1998; 4: 783-9
213. Kaijser GP, Korst A, Beijnen JH, et al. The analysis of ifosfamide and its metabolites. Anticancer Res 1993; 13: 1311-24
214. Boddy AV, Furtun Y, Sardas S, et al. Individual variation in the activation and inactivation of metabolic pathways of cyclophosphamide. J Natl Cancer Inst 1992; 84: 1744-8
215. Wainer IW, Ducharme J, Granvil CP, et al. Ifosfamide stereoselective dechloroethylation and neurotoxicity. Lancet 1994; 383: 982-3
216. Ratner L, Lee J, Tang S, et al. Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. J Clin Oncol 2001; 19 (8): 2171-8
217. Hesse LM, von Moltke LL, Shader RI, et al. Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion. Drug Metab Dispos 2001; 29: 100-2
218. Kumar GN, Dykstra J, Roberts EM, et al. Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: a positive drug-drug interaction. Drug Metab Dispos 1999; 27: 902-8
219. Yu LJ, Drewes P, Gustafsson KG, et al. In vivo modulation of alternative pathways of P-450-catalyzed cyclophosphamide metabolism: impact on pharmacokinetics and antitumor activity. J Pharmacol Exp Ther 1999; 288: 928-37
220. Granvil CP, Wang T, Batist G, et al. Influence of phenobarbital induction on the enantioselective N-dechloroethylation of ifosfamide enantiomers in the rat. Drug Metab Dispos 1994; 22: 165-7
221. Villikka K, Kivisto KT, Neuvonen PJ. The effect of dexamethasone on the pharmacokinetics of triazolam. Pharmacol Toxicol 1998; 83: 135-8
222. Kerbusch T, Jansen RLH, Mathot RAA, et al. Modulation of the cytochrome P450-mediated metabolism of ifosfamide by ketoconazole and rifampin. Clin Pharmacol Ther 2001; 70: 132-41
223. Lindley C, Hamilton G, McCune JS, et al. The effect of cyclophosphamide with and without dexamethasone on cytochrome P450 3A4 and 2B6 in human hepatocytes. Drug Metab Dispos 2002; 30: 814-22
224. Chang TK, Yu L, Maurel P, et al. Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines. Cancer Res 1997; 15: 1946-54
225. Boddy AV, Yule SM. Metabolism and pharmacokinetics of oxazaphosphorines. Clin Pharmacokinet 2000; 38: 291-304
226. Gatti G, De Pascalis CR, Toffoli G, et al. Case control study of indinavir pharmacokinetics in patients undergoing chemotherapy for AIDS related neoplasia [abstract no. 1.05]. 2nd International Workshop on Clinical Pharmacology of HIV Therapy; 2001 Apr 2-4; Noordwijk
227. Rosenthal E, Poizot-Martin I, Saint-Marc T, et al. Phase IV study of liposomal daunorubicin (Daunoxome) in AIDS-related Kaposi Sarcoma. Am J Clin Oncol 2002; 25 (1): 57-9
228. Stewart S, Jablonowski H, Goebel FD, et al. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. J Clin Oncol 1998; 16: 683-91
229. Northfelt DW, Dezube BJ, Thommes JA, et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J Clin Oncol 1998; 16: 2445-51
230. Nunez M, Saballs P, Valencia ME, et al. Response to liposomal doxorubicin and clinical outcome of HIV-1 infected patients with Kaposi's sarcoma receiving highly active antiretroviral therapy. HIV Clin Trials 2001; 2: 429-37
231. Rajagopalan S, Politi P, Sinha BK, et al. Adriamycin induced free radical formation in the perfused rat heart: implications for cardiotoxicity. Cancer Res 1988; 48: 4766-9
232. Myers CE, McGuire WP, Liss RH, et al. Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science 1977; 197: 165-7
233. Gerwitz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 1999; 57: 727-41
234. Gabizon A, Catane R, Uziely B, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1994; 54: 987-92
235. Toffoli G, Corona G, Cattarossi G, et al. Effect of highly active antiretroviral therapy (HAART) on pharmacokinetics and pharmacodynamics of doxorubicin in patients with HIV-associated non-Hodgkin's lymphoma. Ann Oncol 2004; 15: 1805-9
236. Zhao XJ, Jones DR, Wang YH, et al. Reversible and irreversible inhibition of CYP3A enzymes by tamoxifen and metabolites. Xenobiotica 2002; 10: 863-78
237. Sridar C, Kent UM, Notley LM, et al. Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6. J Pharmacol Exp Ther 2002; 301: 945-52
238. Dowsett M, Pfister C, Johnston SRD, et al. Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer. Clin Cancer Res 1999; 5: 2338-43
239. Grimm SW, Dyroff MC. Inhibition of human drug metabolizing cytochromes P450 by anastrozole, a potent and selective inhibitor of aromatase. Drug Metab Dispos 1997; 25: 598-602
240. Lin FI. Rifampin-induced deterioration in steroid-dependent asthma. J Allergy Clin Immunol 1996; 98: 1125
241. Bartoszek M, Brenner AM, Szefler SJ. Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy. Clin Pharmacol Ther 1987; 42: 424-32
242. Carrie F, Roblot P, Bouquet S, et al. Rifampin-induced nonresponsiveness of giant cell arteritis to prednisone treatment. Arch Intern Med 1994; 154: 1521-4
243. Thiebaut F, Tsuruo T, Hamada H, et al. Cellular localization of the multidrug resistance gene product in normal human tissues. Proc Natl Acad Sci U S A 1987; 84: 7735-8
244. Cordon-Cardo C, O'Brien JP, Casals D, et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci U S A 1989; 86: 695-8
245. Van Asperen J, Van Tellingen O, Beijnen JH. The pharmacological role of p-glycoprotein in the intestinal epithelium. Pharmacol Res 1998; 37: 429-35
246. Schellens JHM, Malingre MM, Kruitjzer CMF, et al. Modulation of oral bioavailability of anticancer drugs: from mouse to man. Eur J Pharm Sci 2000; 12: 103-10
247. Matheny CJ, Lamb MW, Brouwer KLR, et al. Pharmacokinetic and pharmacodynamic implications of p-glycoprotein modulation. Pharmacotherapy 2001; 21: 778-96
248. Stormer E, von Moltke LL, Perloff MD, et al. Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture. Pharm Res 2002; 19: 1038-45
249. Drewe J, Gutmann H, Pricker G, et al. HIV protease inhibitor ritonavir: a more potent inhibitor of p-glycoprotein than the cyclosporine analog SDZ PSC 833. Biochem Pharmacol 1999; 57: 1147-52
250. Washington CB, Duran GE, Man MC, et al. Interaction of anti-HIV protease inhibitors with the multidrug transporter p-glycoprotein (P-gp) in human cultured cells. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 19: 203-9
251. Srinivas RV, Middlemas D, Flynn P, et al. Human immunodeficiency virus protease inhibitors serve as substrates for multidrug transporter proteins MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters. Antimicrob Agents Chemother 1998; 42: 3157-62
252. Perloff MD, von Moltke LL, Marchand JE, et al. Ritonavir induces p-glycoprotein expression, mutidrug resistance-associated protein (MRP1) expression, and drug transporter-mediated activity in a human intestinal cell line. J Pharm Sci 2001; 90: 1829-37
253. Huang L, Wring SA, Woolley JL, et al. Induction of p-glycoprotein and cytochrome P-450 3A by HIV protease inhibitors. Drug Metab Dispos 2001; 29: 754-60
254. Washington CB, Wiltshire HR, Man M, et al. The disposition of saquinavir in normal and p-glycoprotein deficient mice, rats, and in cultured cells. Drug Metab Dispos 2000; 28: 1058-62
255. Choo EF, Leake B, Wandel C, et al. Pharmacological inhibition of p-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drag Metab Dispos 2000; 28: 655-60
256. Kim RB, Fromm MF, Wandel C, et al. The drug transporter p-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998; 101: 289-94
257. Lucia MB, Rutella S, Leone G, et al. In vitro and in vivo modulation of MDR1/p-glycoprotein in HIV-infected patients administered highly active antiretroviral therapy and liposomal doxorubicin. J Acquir Immune Defic Syndr Hum Retrovirol 2002; 30: 369-78
258. Gill PS, Miles SA, Mitsuyasu RT, et al. Phase I AIDS Clinical Trials Group (075) study of adriamycin, bleomycin and vincristine chemotherapy with zidovudine in the treatment of AIDS-related Kaposi's sarcoma. AIDS 1994; 8: 1695-9
259. Walker RE, Parker RI, Kovacs JA, et al. Anemia and erythropoiesis in patients with the acquired immunodeficiency syndrome (AIDS) and Kaposi sarcoma treated with zidovudine. Ann Intern Med 1988; 108: 372-6
260. Gill PS, Mitsuyasu RT, Montgomery T, et al. AIDS Clinical Trials Group Study 094: a phase I/II trial of ABV chemotherapy with zidovudine and recombinant human GM-CSF in AIDS-related Kaposi's sarcoma. Cancer J Sci Am 1997; 3: 278-83
261. Moyle GJ, Sadler M. Peripheral neuropathy with nucleoside antiretrovirals: risk factors, incidence and management. Drug Saf 1998; 19: 481-94